The development of resistance through BRAF-inhibitor bypass and the emergence of RAS-driven secondary cancers in response to BRAF inhibition has necessitated the exploration of combination therapies involving both BRAF and MEK inhibitors. The gene discussed is BRAF; the disease is cancer.